Form 4: Sera Prognostics Chief Data Officer Reports Stock Transactions

Paul Kearney, Chief Data Officer of Sera Prognostics, reports acquisition and disposal of Class A Common Stock and stock options.

Summary

• On March 5, 2025, Paul Kearney, Chief Data Officer of Sera Prognostics, acquired 47,010 shares of Class A Common Stock represented by restricted stock units (RSUs) at $0.
• These RSUs vest over four years, with 1/16 vesting quarterly starting March 10, 2025, contingent on continued service to the issuer.
• On March 6, 2025, Kearney sold 1,338 shares of Class A Common Stock at $4.16 per share to cover tax withholding obligations related to the vesting of RSUs.
• The sale was mandated by the issuer's 'sell to cover' policy and wasn't a discretionary transaction.
• Kearney also acquired 67,810 stock options with an exercise price of $4.20 on March 5, 2025.
• These options vest over four years, with 1/48 vesting monthly starting March 10, 2025, contingent on continued service.
• Following these transactions, Kearney beneficially owns 203,800 shares of Class A Common Stock and 67,810 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations. There's no indication of significant positive or negative sentiment.

Positives

• The acquisition of RSUs and stock options indicates confidence in the company's future by a key executive.
• The vesting schedule of the RSUs and stock options incentivizes continued service and commitment from the Chief Data Officer.

Negatives

• The sale of shares to cover tax obligations, while not discretionary, could be perceived negatively by some investors.

Risks

• The vesting of RSUs and stock options is contingent on continued service, creating a potential risk if the executive leaves the company.
• Market fluctuations could impact the value of the shares and options, affecting the executive's holdings.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future actions.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• Vesting schedules of four years are typical for such grants, ensuring long-term commitment from executives.
• The 'sell to cover' practice for tax obligations is also a standard procedure to simplify tax management for employees and the company.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they involve a relatively small number of shares.
• Employees are affected by the company's 'sell to cover' policy for tax obligations.

Key Dates